On the Record · Organon
Organon acquisitions, on the record
The businesses Organon bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Claria Medical, Inc. ("Claria")Word for word“In January 2023, the Company made a strategic investment in Claria, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.” 10-K for 2023 | agreed acquisition | In January 2023 | — |
Lilly's migraine medicines Emgality and Rayvow (sole distributor and promoter in Europe)Word for word“In December 2023, we announced an agreement with Lilly to become the sole distributor and promoter for the migraine medicines Emgality ® 2 (galcanezumab) and Rayvow ™ 2 (lasmiditan) in Europe.” 10-K for 2023 | agreed acquisition | In December 2023 | — |
Alydia HealthWord for word“We acquired Jada as part of our acquisition of Alydia Health in June 2021.” 10-K for 2023 | acquisition | June 2021 | — |
Dermavant Sciences Ltd.Word for word“On October 28, 2024, we acquired Dermavant, a company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology.” 10-K for 2024 | acquisition | October 28, 2024 | — |
Jada SystemWord for word“In pursuit of our strategy, in January 2026, we divested the Jada System to Laborie for an aggregate payment of up to $465 million, comprised of consideration of $440 million, subject to certain closing adjustments, plus potential earnout payments of up to $25 million based on the achievement of certain 2026 net sales targets.” 10-K for 2025 | divestiture | January 2026 | up to $465 million |
Tofidence (regulatory and commercial rights in the United States, from Biogen)Word for word“In March 2025, we acquired from Biogen the regulatory and commercial rights in the United States for Tofidence , a biosimilar to Actemra 2 (tocilizumab), for intravenous infusion.” 10-K for 2025 | acquisition | March 2025 | — |
| Fiscal year ended | Goodwill from acquisitions |
|---|---|
| 2023-12-31 | $0 |
| 2024-12-31 | $77 million |
| 2025-12-31 | $0 |
Deal filings since 2016
- 2026-04-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-09-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-05-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-07-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-03 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
Read from Organon’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.